Discover

ABT
Abbott Laboratories
91.13
500 x 91.18
400 x 91.58
bid
ask
-
1.35
1.46%
450 @ 04:01 PM
91.49 +0.36 (0.40%)
Ytd -27.26%
1y -29.56%
91.06
day range
92.64
91.13
52 week range
138.08
Open 92.15 Prev Close 92.48 Low 91.06 High 92.64 Mkt Cap 158.36B
Vol 12.64M Avg Vol 11.88M EPS 3.52 P/E 25.89 Forward P/E 15.24
Beta 0.78 Short Ratio 1.93 Inst. Own 82.10% Dividend 2.52 Div Yield 2.75
Ex Div Date 04-15 Earning 07-16 50-d Avg 106.58 200-d Avg 121.78 1yr Est 118.64
Earning
Date For Estimate Reported Surprise surprise %
2026-04-16 2026-03 1.14 1.15 0.01 0.88%
2026-01-22 2025-12 1.5 1.5 N/A N/A
2025-10-15 2025-09 1.3 1.3 N/A N/A
2025-07-17 2025-06 1.25 1.26 0.01 0.80%
2025-04-16 2025-03 1.07 1.09 0.02 1.87%
2025-01-22 2024-12 1.34 1.34 N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2026-04-20 Barclays Upgrade Overweight Overweight
2026-04-17 Piper Sandler Upgrade Overweight Overweight
2026-04-17 Oppenheimer Upgrade Outperform Outperform
2026-04-17 RBC Capital Upgrade Outperform Outperform
2026-04-17 Benchmark Upgrade Buy Buy
2026-04-17 Evercore ISI Group Upgrade Outperform Outperform
Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Insider Holder
Date Name Relation Quantity Description
2025-02-24 ALLEN HUBERT L. Officer 200.28K Stock Award(Grant)
2026-02-23 BOUDREAU PHILIP P Chief Financial Officer 78.98K Stock Award(Grant)
2026-02-23 EARNHARDT LISA D Officer 98.98K Stock Award(Grant)
2026-02-23 FORD ROBERT B. Chief Executive Officer 552.97K Stock Award(Grant)
2024-05-09 FUNCK ROBERT E. JR. Officer 270.61K Sale
2026-03-01 MORELAND MARY K Officer 116.14K Sale
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 175.56M 16.00B 10.08%
2025-12-30 Blackrock Inc. 146.91M 13.39B 8.43%
2025-12-30 State Street Corporation 79.85M 7.28B 4.58%
2025-12-30 Capital International Investors 63.23M 5.76B 3.63%
2025-12-30 Capital Research Global Investors 39.17M 3.57B 2.25%
2025-12-30 Geode Capital Management, LLC 38.41M 3.50B 2.21%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 54.65M 4.98B 3.14%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 43.85M 4.00B 2.52%
2026-02-27 Fidelity Concord Street Trust-Fidelity 500 Index Fund 22.13M 2.02B 1.27%
2026-02-27 iShares Trust-iShares Core S&P 500 ETF 22.17M 2.02B 1.27%
2026-03-30 SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust 20.15M 1.84B 1.16%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Value Index Fund 16.00M 1.46B 0.92%
Dividend
Dividend Date
0.63 2026-04-15
0.63 2026-01-15
0.59 2025-10-15
0.59 2025-07-15
0.59 2025-04-15
0.59 2025-01-15
Split
Split Date
10000 : 4798 2013-01-02
2.0842 : 1 2013-01-01
10000 : 9356 2004-05-03
1.06883 : 1 2004-05-02
2 : 1 1998-06-01
2 : 1 1992-06-01